Search Result

Results for "

radiosensitivity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (2) ATM/ATR (1) Aurora Kinase (1) Autophagy (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) c-Met/HGFR (2) DNA/RNA Synthesis (1) Drug Metabolite (3) E1/E2/E3 Enzyme (4) Endogenous Metabolite (5) HDAC (1) Isotope-Labeled Compounds (2) NF-κB (1) PARP (1) Phosphatase (1)
By Research Areas:	Cancer (19) Infection (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100683

A12B4C3	Phosphatase	Cancer
A12B4C3 is a potent human polynucleotide kinase/phosphatase (hPNKP) inhibitor with an IC₅₀ value of 0.06 μM. A12B4C3 has antiproliferative activity against cancer cells. A12B4C3 can also enhance the radiosensitivity of certain cancer cells .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available PARP inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-134594

SENP1-IN-1	E1/E2/E3 Enzyme	Cancer
SENP1-IN-1 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 29. SENP1-IN-1 is developed for tumor radiosensitivity enhancement .

HY-134597

SENP1-IN-4	E1/E2/E3 Enzyme	Cancer
SENP1-IN-4 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 21. SENP1-IN-4 is developed for tumor radiosensitivity enhancement .

HY-134596

SENP1-IN-3	E1/E2/E3 Enzyme	Cancer
SENP1-IN-3 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 17. SENP1-IN-3 is developed for tumor radiosensitivity enhancement .

HY-162002

WSD0628	ATM/ATR	Cancer
WSD0628 is a brain penetrant and potent ATM inhibitor with profound radiosensitizing effect .

HY-W008449

1-Methylxanthine	Drug Metabolite Endogenous Metabolite	Cancer
1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP) . 1-Methylxanthine enhances the radiosensitivity of tumor cells .

HY-164539

TMU 35435	HDAC Autophagy	Cancer
TMU 35435 is a histone deacetylase (HDAC) inhibitor. TMU-35435 inhibits the NHEJ pathway through ubiquitination of DNA-dependent protein kinase catalytic subunit (DNA-PKcs). In addition, TMU 35435 enhances radiosensitivity by inducing misfolded protein aggregation and autophagy in TNBC .

HY-134595

SENP1-IN-2	E1/E2/E3 Enzyme	Cancer
SENP1-IN-2 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 30. SENP1-IN-2 is developed for tumor radiosensitivity enhancement .

HY-121648

PK 130	Biochemical Assay Reagents	Cancer
PK 130 is a 2-nitroimidazole derivative that has radiosensitizing effects on hypoxic cells. PK 130 increases the radiosensitivity of Chinese hamster V79 cells under hypoxic conditions .

HY-139289S

ART899	DNA/RNA Synthesis	Cancer
ART899 is a highly specific allosteric inhibitor of the Polθ DNA polymerase domain. ART899 can effectively enhance the radiosensitivity of tumor cells, shows good tolerance when combined with fractionated radiation, and significantly reduces tumor growth compared to radiation alone .

HY-120429

SKLB-163	Apoptosis	Cancer
SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis .

HY-W008449R

1-Methylxanthine (Standard)	Drug Metabolite Endogenous Metabolite	Cancer
1-Methylxanthine (Standard) is the analytical standard of 1-Methylxanthine. This product is intended for research and analytical applications. 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP) . 1-Methylxanthine enhances the radiosensitivity of tumor cells .

HY-W008449S2

1-Methylxanthine-d3	Drug Metabolite Endogenous Metabolite Isotope-Labeled Compounds	Cancer
1-Methylxanthine-d₃ is deuterated labeled 1-Methylxanthine (HY-W008449). 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP) . 1-Methylxanthine enhances the radiosensitivity of tumor cells .

HY-W008449S

1-Methylxanthine-13C,d3	Isotope-Labeled Compounds Endogenous Metabolite	Cancer
1-Methylxanthine- ¹³C,d₃ is the ¹³C- and deuterium labeled 1-Methylxanthine. 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP)[1]. 1-Methylxanthine enhances the radiosensitivity of tumor cells[2].

HY-W008449S1

1-Methylxanthine-13C4,15N3	Endogenous Metabolite	Cancer
1-Methylxanthine- ¹³C₄, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled 1-Methylxanthine. 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP)[1]. 1-Methylxanthine enhances the radiosensitivity of tumor cells[2].

HY-10180A

MLN8054 sodium	Aurora Kinase	Cancer
MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy .

HY-N4327

Eurycomalactone	NF-κB Apoptosis Akt Bcl-2 Family	Infection Inflammation/Immunology
Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC₅₀ value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF-κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394) .

HY-13299

MK-8033 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

HY-13299A

MK-8033 hydrochloride 2 Publications Verification	c-Met/HGFR	Cancer
MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC₅₀s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .

Cat. No.	Product Name

HY-L179

Radiosensitizer Library	41 compounds
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells. MCE designs a unique collection of 41 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Radiosensitizer Library

41 compounds

Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.

MCE designs a unique collection of 41 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Cat. No.	Product Name	Category	Target	Chemical Structure